Chifeng Biological has made new progress in a variety of independently developed products.

According to Chia Tai Bio message, in recent days, Chia Tai Bio has made positive progress in the independent research and development of multiple products. Among them, the adsorbed acellular pertussis combination vaccine has officially received the clinical trial approval notice issued by the National Medical Products Administration; the freeze-dried varicella inactivated vaccine, and the herpes zoster mRNA vaccine clinical trial applications have also been accepted by the National Medical Products Administration. As of now, the company has a total of 33 independently developed projects, with 22 projects in the stages of application, conducting clinical trials, and applying for marketing authorization.